

**Notice of Completion of Acquisition of Own Shares  
(Under the provision of its Articles of Incorporation in  
accordance with Article 165, paragraph 2 of the Companies Act)**

Tokyo, March 23, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on January 31, 2017, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

- |                                          |                                         |
|------------------------------------------|-----------------------------------------|
| 1. Class of shares acquired:             | Common stock of the Company             |
| 2. Total number of shares acquired:      | 30,000,000 shares                       |
| 3. Aggregate amount of acquisition cost: | 45,525,514,216 yen                      |
| 4. Period of acquisition:                | From February 1, 2017 to March 22, 2017 |
| 5. Method of acquisition:                | Purchased on the Tokyo Stock Exchange   |

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on January 31, 2017)

- |                                          |                                                                                                       |
|------------------------------------------|-------------------------------------------------------------------------------------------------------|
| - Class of shares to be acquired:        | Common stock of the Company                                                                           |
| - Total number of shares to be acquired: | Up to 30 million shares<br>(The percentage compared to the total number of shares outstanding: 1.43%) |
| - Aggregate amount of acquisition cost:  | Up to 50 billion yen                                                                                  |
| - Period of acquisition:                 | From February 1, 2017 to March 24, 2017                                                               |

#####

### **About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at [www.astellas.com/en](http://www.astellas.com/en).

### **Cautionary Notes**

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

### **Contacts for inquiries or additional information:**

---

Astellas Pharma Inc.  
Corporate Communications  
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473